Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia
{{output}}
Background: Non-small cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor exon 20 (EGFR Ex20Ins) is rare and resistant to conventional tyrosine kinase inhibitors (TKIs), limiting treatment options. This re... ...
